Stroke Prevention Research Unit, University Department of Clinical Neurology, Level 6, West Wing, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU.
Stroke. 2010 Jun;41(6):1222-8. doi: 10.1161/STROKEAHA.109.572594. Epub 2010 Apr 29.
Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs. Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB.
In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01). There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01). There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P<0.001; P difference=0.25). In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4-42.5; P<0.001).
The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH. Limited prospective data corroborate these findings, but larger prospective studies are urgently required.
脑微出血(MB)是脑出血(ICH)的潜在危险因素,但尚不清楚其是否为抗血栓药物禁忌证。通过对ICH 和缺血性卒中和短暂性脑缺血发作(TIA)队列中按抗血栓药物使用分层的 MB 频率进行数据汇总,可以获得一些见解。
我们对发表和未发表的来自卒中和 TIA 队列的数据进行了系统回顾,以比较以下情况下的 MB 存在情况:(1)抗血栓药物使用者与 ICH 中的非抗血栓药物使用者;(2)抗血栓药物使用者与 IS/TIA 中的非使用者;以及(3)按抗血栓药物使用分层的 ICH 与缺血性事件。我们还分析了发表和未发表的随访数据,以确定 MB 存在的抗血栓药物使用者发生 ICH 的风险。
在对 1460 例 ICH 和 3817 例 IS/TIA 的汇总分析中,所有治疗组中,ICH 中的 MB 比 IS/TIA 更常见,但在非抗血栓药物使用者中,从 2.8(比值比;范围,2.3-3.5)增加到抗血小板药物使用者的 5.7(范围,3.4-9.7)和华法林使用者的 8.0(范围,3.5-17.8)(P 差异=0.01)。华法林使用者与 ICH 非使用者相比,MB 也存在过度(OR,2.7;95%CI,1.6-4.4;P<0.001),但在华法林使用者与 IS/TIA 相比,MB 则不存在(OR,1.3;95%CI,0.9-1.7;P=0.33;P 差异=0.01)。与 ICH 非使用者相比,抗血小板药物使用者的 MB 过度程度较小(OR,1.7;95%CI,1.3-2.3;P<0.001),但在抗血小板药物使用者与 IS/TIA 中,结果相似(OR,1.4;95%CI,1.2-1.7;P<0.001;P 差异=0.25)。在 768 例抗血栓药物使用者的汇总随访数据中,基线时存在 MB 与随后发生 ICH 的风险显著增加相关(OR,12.1;95%CI,3.4-42.5;P<0.001)。
与其他组相比,华法林使用者中 MB 的过度增加表明 MB 增加了华法林相关 ICH 的风险。有限的前瞻性数据证实了这些发现,但迫切需要更大规模的前瞻性研究。